Supplementary file 1

Firouzi et al., ***BioImpacts,*** 2022
doi: 10.34172/bi.2022.23336
http://bi.tbzmed.ac.ir/

Silibinin exhibits anti-tumor effects in a breast cancer stem cell model by targeting stemness and induction of differentiation and apoptosis

Javad Firouzi[1], Alireza Shokouhifar[1], Mahsa Rahimi[1], Fattah Sotoodehnejadnematalahi[2], Niloufar Sodeifi[3], Parisa Sahranavardfar[1], Masoumeh Azimi[1], Ehsan Janzamin[1], Marzieh Ebrahimi[1*]

[1] Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 16635-148

[2]Department of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, 1477893855

[3]Department of Pathology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran



Figure S1. FSC and SSC gating approach for gating viable cancer stem cells. The circle shows the viable cells. FSC, forward scatter; SSC, side scatter.



Figure S2. MFI of CD44/CD24 and CD44/CD133 in mammosphere-derived cells from control and treated groups. Simultaneous analysis of (A) CD44 and (B) CD24 MFI in mammosphere-derived cells from treated and untreated MCF-7, MDA-MB-231, and also MDA-MB-468 aggregated cells. Simultaneous analysis of (C) CD44 and (D) CD133 MFI in mammosphere-derived cells from treated and untreated MCF-7, MDA-MB-231, and also MDA-MB-468 aggregated cells. $^{*}P<0.05$, $^{**}P<0.01$. MFI, mean fluorescence index; FL1, fluorescence parameter 1; FITC, fluorescein isothiocyanate; PE, phycoerythrin.